Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: mechanisms of COX-2 inhibitor risk to heart disease
about
DanQi Pill protects against heart failure through the arachidonic acid metabolism pathway by attenuating different cyclooxygenases and leukotrienes B4.Specificity of eicosanoid production depends on the TLR-4-stimulated macrophage phenotype.Mechanism of QSYQ on anti-apoptosis mediated by different subtypes of cyclooxygenase in AMI induced heart failure rats.The Effects of Cyclosporine and Aspirin on Platelet Function in Normal Dogs.5-Lipoxygenase metabolic contributions to NSAID-induced organ toxicity.Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than meets the eye: a critical review.The platelet fibrinogen receptor: from megakaryocyte to the mortuary.Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity.New benzothiophene derivatives as dual COX-1/2 and 5-LOX inhibitors: synthesis, biological evaluation and docking study.Anti-platelet therapy in small animal medicine.Cyclo-oxygenase-1 or -2-mediated metabolism of arachidonic acid in endothelium-dependent contraction of mouse arteries.In vivo Endocrine Secretion of Prostacyclin Following Expression of a Cyclooxygenase-1/Prostacyclin Fusion Protein in the Salivary Glands of Rats Via Nonviral Gene Therapy.Effects of aspirin dose escalation on platelet function and urinary thromboxane and prostacyclin levels in normal dogs.The effects of cyclosporine on platelet function and cyclooxygenase expression in normal dogs.
P2860
Q35098869-A762D8E2-45D5-40C7-99AD-E4F38FFDB5BAQ35170002-767197DC-88A7-4427-9A98-1A315916FBBCQ36135119-77E6FD99-7CC0-4C10-806C-5C113856E02CQ37375461-772818FC-8E11-4FC3-970E-B4A2194E5AC9Q37986694-CA77C190-92F9-4165-A474-96AD5C7CB650Q38068081-8C4BB321-F4E2-418B-BC95-7B517994ECEFQ38156780-BFC1D87B-52BF-4B48-9DDF-AB789B49579CQ38161572-4A242399-F8E0-4C9D-8984-DBD73EA63953Q38737298-096762C3-3910-46A3-8F52-490C97964FD7Q38770733-D6139BE8-CF03-4245-BE68-F7929152B0A6Q44021565-7CDAAE4A-0D0E-437F-874F-E52BB1BDBF45Q45867988-771F3570-66FE-4AB2-8A9F-F007B064FF63Q48196707-A9A357CA-2AE0-4F0C-8CF4-0652BC577D80Q51300207-FA4ABB0D-B563-4E4D-B831-2C38E3C3D1B7
P2860
Inducible COX-2 dominates over COX-1 in prostacyclin biosynthesis: mechanisms of COX-2 inhibitor risk to heart disease
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Inducible COX-2 dominates over ...... nhibitor risk to heart disease
@ast
Inducible COX-2 dominates over ...... nhibitor risk to heart disease
@en
Inducible COX-2 dominates over ...... nhibitor risk to heart disease
@en-gb
Inducible COX-2 dominates over ...... nhibitor risk to heart disease
@nl
type
label
Inducible COX-2 dominates over ...... nhibitor risk to heart disease
@ast
Inducible COX-2 dominates over ...... nhibitor risk to heart disease
@en
Inducible COX-2 dominates over ...... nhibitor risk to heart disease
@en-gb
Inducible COX-2 dominates over ...... nhibitor risk to heart disease
@nl
prefLabel
Inducible COX-2 dominates over ...... nhibitor risk to heart disease
@ast
Inducible COX-2 dominates over ...... nhibitor risk to heart disease
@en
Inducible COX-2 dominates over ...... nhibitor risk to heart disease
@en-gb
Inducible COX-2 dominates over ...... nhibitor risk to heart disease
@nl
P2093
P2860
P3181
P1433
P1476
Inducible COX-2 dominates over ...... nhibitor risk to heart disease
@en
P2093
Cheng-Huai Ruan
Ke-He Ruan
Shui-Ping So
P2860
P3181
P356
10.1016/J.LFS.2010.10.017
P407
P577
2011-01-03T00:00:00Z